Pankaj Bhattarai
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
Publications
13
Citations
131
Est. group size
~3
Recurring co-author estimate
Active years
8
Publishing since 2019
Pankaj Bhattarai's research focuses on designing and evaluating new chemical compounds aimed at fighting tuberculosis and related infections, including studies of how these compounds interact with bacterial proteins like MmpL3. The work combines organic chemistry synthesis with pharmacology and toxicology, aiming to improve drug properties such as how well a compound is absorbed and processed by the body (pharmacokinetics).
Publication output was minimal or absent in the early part of the decade but has increased noticeably in the last two to three years, suggesting a growing recent research output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Structural Determinants of Indole-2-carboxamides: Identification of Lead Acetamides with Pan Antimycobacterial Activity
Journal of Medicinal Chemistry · 2022
- Direct Inhibition of MmpL3 by Novel Antitubercular Compounds
ACS Infectious Diseases · 2019
- Design, Synthesis, and Evaluation of Novel Antimycobacterial Agents With Enhanced Pharmacokinetic Profiles
2019
- ChemRxiv×6
- Journal of Medicinal Chemistry×2
- ACS Infectious Diseases×1
- Nature Communications×1
- Chemical Communications×1
- Trevor A. Trombley
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
- Mohammed K. Abd El‐Gaber
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
- Ryan A. Altman
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
- Aditi Shendre
Pharmacology, Toxicology and Pharmaceutics · The Ohio State University
- Hao Chen
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile